MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation^® technology and ExPERT^™ platform. In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments.

At MaxCyte, our goal is to maximize the potential of cells to improve patients’ lives, and it is through collaborations such as this that we can achieve success. We look forward to supporting Lyell Immunopharma in its development of solid tumor treatments for patients with unmet needs.”

Doug Doerfler, President and CEO, MaxCyte

MaxCyte’s ExPERT^™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT^™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Each of MaxCyte’s strategic partnerships generates pre-commercial milestone revenue and the vast majority include sales-based payments.